A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

• Status: Completed
• Trial end date: 2017-03-24

Summary

The purpose of this phase 3 study is to evaluate the efficacy and safety of ABT-493/ABT-530 in comparison to sofosbuvir plus ribavirin for 12 weeks in Hepatitis C Virus (HCV) Genotype 2 (GT2) infected participants.

• Phase: Phase 3

Details

• Lead Sponsor: AbbVie
• Treatments: Ribavirin; Sofosbuvir